Toll Biotech

Explore the latest insights on Toll Biotech and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Toll Biotech’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Nutshell Therapeutics' NTS231 Clears FDA IND – First NRF2 Molecular Glue Degrader from China and Second Globally to Enter Clinical Development, Targeting KEAP1 to Block NRF2
CompanyDrug

Nutshell Therapeutics’ NTS231 Clears FDA IND – First NRF2 Molecular Glue Degrader from China and Second Globally to Enter Clinical Development, Targeting KEAP1 to Block NRF2

Nutshell Therapeutics announced that NTS231, its independently developed covalent allosteric molecular glue degrader targeting NRF2, has received an IND clearance from the U.S. Food and Drug Administration (FDA), permitting clinical…

Simcere Pharmaceutical Files IND for SIM0688 – First B7‑H3/c‑Met Bispecific ADC to Enter Clinical Development

Simcere Pharmaceutical Files IND for SIM0688 – First B7‑H3/c‑Met Bispecific ADC to Enter Clinical Development

CDE Includes Beijing Toll Biotech's TollB‑001 Tablets in Rare Disease Pilot Scheme – Novel Oral TLR8 Inhibitor Targets Systemic Sclerosis with First Specific Treatment Potential

CDE Includes Beijing Toll Biotech’s TollB‑001 Tablets in Rare Disease Pilot Scheme – Novel Oral TLR8 Inhibitor Targets Systemic Sclerosis with First Specific Treatment Potential

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now